The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
Open accessAbstract
BACKGROUND: To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial. RESULTS: Mortality after two years was significantly lower in the enalapril arm (18 percent) than in the hydralazine-isosorbide dinitrate arm (25 percent) (P = 0.016; reduction in mortality, 28.0 percent), and overall mortality tended to be lower (P = 0.08). The lower mortality in the enalapril arm was attributable to a reduction in the incidence of sudden death, and this beneficial effect was more prominent in patients with less severe symptoms (New York Heart Association class I or II). In contrast, body oxygen consumption at peak exercise was increased only by hydralazine-isosorbide dinitrate treatment (P less than 0.05), and left ventricular ejection fraction, which increased with both regimens during the 2 years after randomization, increased more (P less than 0.05) during the first 13 weeks in the hydralazine-isosorbide dinitrate group. CONCLUSIONS: The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure. The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with enalapril, treatment with H-ISDN provided less mortality reduction after a mean of 2.5 years (32.8% vs 38.2%; P = 0.016) and no difference in hospitalizations.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [78]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citationA placebo-controlled trial of captopril in refractory chronic congestive heart failure
Captopril Multicenter Research Group (1983) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(83)80316-7 · Cited by 588
Vasodilator Therapy of Cardiac Failure
Cohn, J. N., & Franciosa, J. A. (1977) · New England Journal of Medicine · doi:10.1056/nejm197707072970105 · Cited by 483
Self-citationThe role of vasodilator therapy in heart failure
Chatterjee, K., & Parmley, W. W. (1977) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(77)90006-8 · Cited by 315
Vasodilator Therapy for Heart Failure
Cohn, J. N. (1973) · Circulation · doi:10.1161/01.cir.48.1.5 · Cited by 293
Self-citationLeier, C. V., Huss, P., Magorien, R. D., & Unverferth, D. V. (1983) · Circulation · doi:10.1161/01.cir.67.4.817 · Cited by 289
The SOLVD Investigators (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90842-o · Cited by 187
Franciosa, J. A., Goldsmith, S. R., & Cohn, J. N. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90468-4 · Cited by 179
Self-citationCombined Oral Hydralazine-Nitrate Therapy in Left Ventricular Failure
Pierpont, G. L., Cohn, J. N., & Franciosa, J. A. (1978) · CHEST Journal · doi:10.1378/chest.73.1.8 · Cited by 137
Self-citationCreager, M. A., Massie, B. M., Faxon, D. P., Friedman, S. D., Kramer, B. L., Weiner, D. A., Ryan, T. J., Topic, N., & Melidossian, C. D. (1985) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(85)80269-2 · Cited by 129
Levine, T. B., OLIVARI, M. T., Garberg, V. R., Sharkey, S. W., & Cohn, J. N. (1984) · Circulation · doi:10.1161/01.cir.69.3.548 · Cited by 122
Self-citationCurrent therapy of the failing heart.
Cohn, J. N. (1988) · Circulation · doi:10.1161/01.cir.78.5.1099 · Cited by 95
Self-citationClinical and hemodynamic experience with enalapril in congestive heart failure
Cody, R. J. (1985) · The American Journal of Cardiology · doi:10.1016/0002-9149(85)90794-5 · Cited by 45
Packer, M., Medina, N., & Yushak, M. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90212-2 · Cited by 36
Heart failure management: The impact of drug therapy on survival
Francis, G. S. (1988) · American Heart Journal · doi:10.1016/0002-8703(88)90829-0 · Cited by 13
Self-citation
Research works printed but not linked: 1
- Cohn, 1987, Circulation, 76, IV–443
Cited by
Sorted by citations
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Metadata
- Authors
- Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., Bhat, G., Goldman, S., Fletcher, R. D., Doherty, J., Hughes, C. V., Carson, P., Cintron, G., Shabetai, R., & Haakenson, C.
- Affiliations
- University of Minnesota (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1991-08
- Volume
- 325
- Issue
- 5
- Pages
- 303-310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2046383587
- Cited by
- 2,833
- References
- 19
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 27 · 2020: 46 · 2019: 39 · 2018: 51 · 2017: 56 · 2016: 69 · 2015: 59 · 2014: 54 · 2013: 61 · 2012: 56
- FWCI
- 124.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- enalapril, hydralazine, isosorbide dinitrate, chronic congestive heart failure, vasodilator therapy, mortality, sudden death, exercise oxygen consumption, left ventricular ejection fraction, ACE inhibitors, combination therapy, digoxin, diuretics, NYHA functional class
- MeSH terms
- Adolescent, Adult, Aged, Chronic Disease, Death, Sudden, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Enalapril, Physical Exertion, Heart Failure, Hospitalization, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Norepinephrine, Oxygen Consumption, Patient Compliance, Stroke Volume, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
